荷兰肿瘤新冠联盟:全国队列中肿瘤患者COVID-19结局
荷兰肿瘤新冠联盟(DOCC)建立全国性观察性质量登记,纳入351例近5年内诊断或治疗肿瘤的COVID-19患者,其中114例死亡。多变量分析显示年龄≥65岁、男性、既往或其他恶性肿瘤、活动性血液肿瘤或肺癌为死亡独立危险因素,亚组分析中活动性肿瘤患者风险主要由肿瘤类型与年龄决定。
要点
- 活动性血液肿瘤或肺癌患者COVID-19死亡风险升高。
- 年龄≥65岁与男性为独立不良预后因素。
- 应减少脆弱患者暴露并考虑治疗调整与疫苗优先。
核心结论
- 合并血液肿瘤或肺癌的肿瘤患者COVID-19不良结局风险增加。
主要发现
- 351例中114例死亡;年龄≥65岁(p<0.001)、男性(p=0.035)、既往或其他恶性肿瘤(p=0.045)、活动性血液肿瘤(p=0.046)或肺癌(p=0.003)为死亡独立危险因素。
- 活动性肿瘤亚组中,死亡风险主要由肿瘤类型(血液肿瘤或肺癌)与年龄(≥65岁)决定。
临床怎么用
- 疫情期间应避免脆弱肿瘤患者暴露于SARS-CoV-2,并考虑治疗调整与疫苗接种优先。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF THE STUDY: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. METHODS: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients' characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. RESULTS: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years (p < 0.001), male gender (p = 0.035), prior or other malignancy (p = 0.045) and active diagnosis of haematological malignancy (p = 0.046) or lung cancer (p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥65 years). CONCLUSION: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered.
引用
- de Joode K, Dumoulin DW, Tol J, et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020. PMID: 33161241. doi:10.1016/j.ejca.2020.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。